Summary
The global Gene Therapy For Cns Disorders Market is expected to witness a CAGR of xx% over the forecast period 2020-2026 and is expected to reach US$ xx million in 2026, from US$ xx million in 2019.
The Gene Therapy For Cns Disorders Market report highlights product development and growth strategies such as merger and acquisition adopted by market players along with SWOT Analysis, PEST and Porter’s Five Forces analyses of the Gene Therapy For Cns Disorders Market, which highlight the strengths, weaknesses, opportunities, and commination of key companies. Moreover, the report offers two distinct market forecasts, one from the perspective of the producer and another from that of the consumer.
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.
The Key Manufacturers covered in this Report:-
- Gilead (Kite Pharma)
- Amgen (BioVex)
- Novartis
- Roche (Spark Therapeutics)
- Bluebird Bio
- ...
By the Product Type, the market is primarily segmented into:
- Ex Vivo
- In Vivo
- Market segment by Application, split into
- Hospitals
- Clinics
- Others
By Applications, the market is segmented into:
The Report covers the following Regions:
- North America
- United States
- Canada
- Mexico
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Central & South America
- Middle East & Africa
- Turkey
- GCC Countries
- Egypt
- South Africa
Objective of the Gene Therapy For Cns Disorders Market Report:
- To assess the size of the market by value and volume
- Analyze the Gene Therapy For Cns Disorders Market in terms of regions and major countries
- Highlight recent developments and trends in the market
- Offer perceptive data regarding major market players in terms of key developments, strategies, and product portfolio
- Determine share of the Gene Therapy For Cns Disorders Market in terms of various segments such as by product type, application, and end-user
- Offer accurate projection of the market for the forecast period using state-of –the-art tools and the current primary and secondary research approaches
- Discuss major factors that impact growth of the Gene Therapy For Cns Disorders Market
The Gene Therapy For Cns Disorders Market engages the readers with all pivotal approaches to understand their position in the industry based on revenue or sales growth. The report efficiently evaluates the Gene Therapy For Cns Disorders Market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competition in the market. The information in the report is backed by annual company reports, financial reports, press releases, regulatory databases, government documents, and statistical databases.
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders:
- Material suppliers/wholesalers
- Market Distributors/traders
- Regulatory bodies
- Research organizations, and consulting firms
- Commercial research & developments (R&D)
- Trade associations and industry bodies
- Importers and exporters
- End-use industries
Available Customizations:
Custom research is one of the most crucial components of the business strategy that helps an organization gain insight into specific business sector, aligned with its specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Gene Therapy for CNS Disorders Revenue
1.4 Market Analysis by Type
1.4.1 Global Gene Therapy for CNS Disorders Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Ex Vivo
1.4.3 In Vivo
1.5 Market by Application
1.5.1 Global Gene Therapy for CNS Disorders Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends by Regions
2.1 Gene Therapy for CNS Disorders Market Perspective (2015-2026)
2.2 Gene Therapy for CNS Disorders Growth Trends by Regions
2.2.1 Gene Therapy for CNS Disorders Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Gene Therapy for CNS Disorders Historic Market Share by Regions (2015-2020)
2.2.3 Gene Therapy for CNS Disorders Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porters Five Forces Analysis
2.3.5 Gene Therapy for CNS Disorders Market Growth Strategy
2.3.6 Primary Interviews with Key Gene Therapy for CNS Disorders Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy for CNS Disorders Players by Market Size
3.1.1 Global Top Gene Therapy for CNS Disorders Players by Revenue (2015-2020)
3.1.2 Global Gene Therapy for CNS Disorders Revenue Market Share by Players (2015-2020)
3.1.3 Global Gene Therapy for CNS Disorders Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Gene Therapy for CNS Disorders Market Concentration Ratio
3.2.1 Global Gene Therapy for CNS Disorders Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Gene Therapy for CNS Disorders Revenue in 2019
3.3 Gene Therapy for CNS Disorders Key Players Head office and Area Served
3.4 Key Players Gene Therapy for CNS Disorders Product Solution and Service
3.5 Date of Enter into Gene Therapy for CNS Disorders Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Gene Therapy for CNS Disorders Historic Market Size by Type (2015-2020)
4.2 Global Gene Therapy for CNS Disorders Forecasted Market Size by Type (2021-2026)
5 Gene Therapy for CNS Disorders Breakdown Data by Application (2015-2026)
5.1 Global Gene Therapy for CNS Disorders Market Size by Application (2015-2020)
5.2 Global Gene Therapy for CNS Disorders Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Gene Therapy for CNS Disorders Market Size (2015-2020)
6.2 Gene Therapy for CNS Disorders Key Players in North America (2019-2020)
6.3 North America Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
6.4 North America Gene Therapy for CNS Disorders Market Size by Application (2015-2020)
7 Europe
7.1 Europe Gene Therapy for CNS Disorders Market Size (2015-2020)
7.2 Gene Therapy for CNS Disorders Key Players in Europe (2019-2020)
7.3 Europe Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
7.4 Europe Gene Therapy for CNS Disorders Market Size by Application (2015-2020)
8 China
8.1 China Gene Therapy for CNS Disorders Market Size (2015-2020)
8.2 Gene Therapy for CNS Disorders Key Players in China (2019-2020)
8.3 China Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
8.4 China Gene Therapy for CNS Disorders Market Size by Application (2015-2020)
9 Japan
9.1 Japan Gene Therapy for CNS Disorders Market Size (2015-2020)
9.2 Gene Therapy for CNS Disorders Key Players in Japan (2019-2020)
9.3 Japan Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
9.4 Japan Gene Therapy for CNS Disorders Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Gene Therapy for CNS Disorders Market Size (2015-2020)
10.2 Gene Therapy for CNS Disorders Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
10.4 Southeast Asia Gene Therapy for CNS Disorders Market Size by Application (2015-2020)
11 India
11.1 India Gene Therapy for CNS Disorders Market Size (2015-2020)
11.2 Gene Therapy for CNS Disorders Key Players in India (2019-2020)
11.3 India Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
11.4 India Gene Therapy for CNS Disorders Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Gene Therapy for CNS Disorders Market Size (2015-2020)
12.2 Gene Therapy for CNS Disorders Key Players in Central & South America (2019-2020)
12.3 Central & South America Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
12.4 Central & South America Gene Therapy for CNS Disorders Market Size by Application (2015-2020)
13Key Players Profiles
13.1 Gilead (Kite Pharma)
13.1.1 Gilead (Kite Pharma) Company Details
13.1.2 Gilead (Kite Pharma) Business Overview and Its Total Revenue
13.1.3 Gilead (Kite Pharma) Gene Therapy for CNS Disorders Introduction
13.1.4 Gilead (Kite Pharma) Revenue in Gene Therapy for CNS Disorders Business (2015-2020))
13.1.5 Gilead (Kite Pharma) Recent Development
13.2 Amgen (BioVex)
13.2.1 Amgen (BioVex) Company Details
13.2.2 Amgen (BioVex) Business Overview and Its Total Revenue
13.2.3 Amgen (BioVex) Gene Therapy for CNS Disorders Introduction
13.2.4 Amgen (BioVex) Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
13.2.5 Amgen (BioVex) Recent Development
13.3 Novartis
13.3.1 Novartis Company Details
13.3.2 Novartis Business Overview and Its Total Revenue
13.3.3 Novartis Gene Therapy for CNS Disorders Introduction
13.3.4 Novartis Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
13.3.5 Novartis Recent Development
13.4 Roche (Spark Therapeutics)
13.4.1 Roche (Spark Therapeutics) Company Details
13.4.2 Roche (Spark Therapeutics) Business Overview and Its Total Revenue
13.4.3 Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Introduction
13.4.4 Roche (Spark Therapeutics) Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
13.4.5 Roche (Spark Therapeutics) Recent Development
13.5 Bluebird Bio
13.5.1 Bluebird Bio Company Details
13.5.2 Bluebird Bio Business Overview and Its Total Revenue
13.5.3 Bluebird Bio Gene Therapy for CNS Disorders Introduction
13.5.4 Bluebird Bio Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
13.5.5 Bluebird Bio Recent Development
14Analyst's Viewpoints/Conclusions
15Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
List of Table
List of Tables
Table 1. Gene Therapy for CNS Disorders Key Market Segments
Table 2. Key Players Covered: Ranking by Gene Therapy for CNS Disorders Revenue
Table 3. Ranking of Global Top Gene Therapy for CNS Disorders Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Gene Therapy for CNS Disorders Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Ex Vivo
Table 6. Key Players of In Vivo
Table 7. Global Gene Therapy for CNS Disorders Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Gene Therapy for CNS Disorders Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Gene Therapy for CNS Disorders Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Gene Therapy for CNS Disorders Market Share by Regions (2015-2020)
Table 11. Global Gene Therapy for CNS Disorders Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Gene Therapy for CNS Disorders Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Gene Therapy for CNS Disorders Market Growth Strategy
Table 17. Main Points Interviewed from Key Gene Therapy for CNS Disorders Players
Table 18. Global Gene Therapy for CNS Disorders Revenue by Players (2015-2020) (Million US$)
Table 19. Global Gene Therapy for CNS Disorders Market Share by Players (2015-2020)
Table 20. Global Top Gene Therapy for CNS Disorders Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Therapy for CNS Disorders as of 2019)
Table 21. Global Gene Therapy for CNS Disorders by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Gene Therapy for CNS Disorders Product Solution and Service
Table 24. Date of Enter into Gene Therapy for CNS Disorders Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 27. Global Gene Therapy for CNS Disorders Market Size Share by Type (2015-2020)
Table 28. Global Gene Therapy for CNS Disorders Revenue Market Share by Type (2021-2026)
Table 29. Global Gene Therapy for CNS Disorders Market Size Share by Application (2015-2020)
Table 30. Global Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 31. Global Gene Therapy for CNS Disorders Market Size Share by Application (2021-2026)
Table 32. North America Key Players Gene Therapy for CNS Disorders Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Gene Therapy for CNS Disorders Market Share (2019-2020)
Table 34. North America Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 35. North America Gene Therapy for CNS Disorders Market Share by Type (2015-2020)
Table 36. North America Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 37. North America Gene Therapy for CNS Disorders Market Share by Application (2015-2020)
Table 38. Europe Key Players Gene Therapy for CNS Disorders Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Gene Therapy for CNS Disorders Market Share (2019-2020)
Table 40. Europe Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Gene Therapy for CNS Disorders Market Share by Type (2015-2020)
Table 42. Europe Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Gene Therapy for CNS Disorders Market Share by Application (2015-2020)
Table 44. China Key Players Gene Therapy for CNS Disorders Revenue (2019-2020) (Million US$)
Table 45. China Key Players Gene Therapy for CNS Disorders Market Share (2019-2020)
Table 46. China Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 47. China Gene Therapy for CNS Disorders Market Share by Type (2015-2020)
Table 48. China Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 49. China Gene Therapy for CNS Disorders Market Share by Application (2015-2020)
Table 50. Japan Key Players Gene Therapy for CNS Disorders Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Gene Therapy for CNS Disorders Market Share (2019-2020)
Table 52. Japan Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Gene Therapy for CNS Disorders Market Share by Type (2015-2020)
Table 54. Japan Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Gene Therapy for CNS Disorders Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Gene Therapy for CNS Disorders Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Gene Therapy for CNS Disorders Market Share (2019-2020)
Table 58. Southeast Asia Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Gene Therapy for CNS Disorders Market Share by Type (2015-2020)
Table 60. Southeast Asia Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Gene Therapy for CNS Disorders Market Share by Application (2015-2020)
Table 62. India Key Players Gene Therapy for CNS Disorders Revenue (2019-2020) (Million US$)
Table 63. India Key Players Gene Therapy for CNS Disorders Market Share (2019-2020)
Table 64. India Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 65. India Gene Therapy for CNS Disorders Market Share by Type (2015-2020)
Table 66. India Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 67. India Gene Therapy for CNS Disorders Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Gene Therapy for CNS Disorders Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Gene Therapy for CNS Disorders Market Share (2019-2020)
Table 70. Central & South America Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Gene Therapy for CNS Disorders Market Share by Type (2015-2020)
Table 72. Central & South America Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Gene Therapy for CNS Disorders Market Share by Application (2015-2020)
Table 74. Gilead (Kite Pharma) Company Details
Table 75. Gilead (Kite Pharma) Business Overview
Table 76. Gilead (Kite Pharma) Product
Table 77. Gilead (Kite Pharma) Revenue in Gene Therapy for CNS Disorders Business (2015-2020) (Million US$)
Table 78. Gilead (Kite Pharma) Recent Development
Table 79. Amgen (BioVex) Company Details
Table 80. Amgen (BioVex) Business Overview
Table 81. Amgen (BioVex) Product
Table 82. Amgen (BioVex) Revenue in Gene Therapy for CNS Disorders Business (2015-2020) (Million US$)
Table 83. Amgen (BioVex) Recent Development
Table 84. Novartis Company Details
Table 85. Novartis Business Overview
Table 86. Novartis Product
Table 87. Novartis Revenue in Gene Therapy for CNS Disorders Business (2015-2020) (Million US$)
Table 88. Novartis Recent Development
Table 89. Roche (Spark Therapeutics) Company Details
Table 90. Roche (Spark Therapeutics) Business Overview
Table 91. Roche (Spark Therapeutics) Product
Table 92. Roche (Spark Therapeutics) Revenue in Gene Therapy for CNS Disorders Business (2015-2020) (Million US$)
Table 93. Roche (Spark Therapeutics) Recent Development
Table 94. Bluebird Bio Company Details
Table 95. Bluebird Bio Business Overview
Table 96. Bluebird Bio Product
Table 97. Bluebird Bio Revenue in Gene Therapy for CNS Disorders Business (2015-2020) (Million US$)
Table 98. Bluebird Bio Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gene Therapy for CNS Disorders Market Share by Type: 2020 VS 2026
Figure 2. Ex Vivo Features
Figure 3. In Vivo Features
Figure 4. Global Gene Therapy for CNS Disorders Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Others Case Studies
Figure 8. Gene Therapy for CNS Disorders Report Years Considered
Figure 9. Global Gene Therapy for CNS Disorders Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Gene Therapy for CNS Disorders Market Share by Regions: 2020 VS 2026
Figure 11. Global Gene Therapy for CNS Disorders Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Gene Therapy for CNS Disorders Market Share by Players in 2019
Figure 14. Global Top Gene Therapy for CNS Disorders Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Therapy for CNS Disorders as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Gene Therapy for CNS Disorders Revenue in 2019
Figure 16. North America Gene Therapy for CNS Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Gene Therapy for CNS Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Gene Therapy for CNS Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Gene Therapy for CNS Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Gene Therapy for CNS Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Gene Therapy for CNS Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Gene Therapy for CNS Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Gilead (Kite Pharma) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 24. Gilead (Kite Pharma) Revenue Growth Rate in Gene Therapy for CNS Disorders Business (2015-2020)
Figure 25. Amgen (BioVex) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Amgen (BioVex) Revenue Growth Rate in Gene Therapy for CNS Disorders Business (2015-2020)
Figure 27. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Novartis Revenue Growth Rate in Gene Therapy for CNS Disorders Business (2015-2020)
Figure 29. Roche (Spark Therapeutics) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Roche (Spark Therapeutics) Revenue Growth Rate in Gene Therapy for CNS Disorders Business (2015-2020)
Figure 31. Bluebird Bio Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Bluebird Bio Revenue Growth Rate in Gene Therapy for CNS Disorders Business (2015-2020)
Figure 33. Bottom-up and Top-down Approaches for This Report
Figure 34. Data Triangulation
Figure 35. Key Executives Interviewed
Request Discount 
Inquire Before Buy
